Adamas Pharmaceuticals Stock Forecast, Price & News

+0.08 (+1.67 %)
(As of 09/23/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume71,301 shs
Average Volume443,456 shs
Market Capitalization$221.60 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ADMS News and Ratings via Email

Sign-up to receive the latest news and ratings for Adamas Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Adamas Pharmaceuticals logo

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.26 out of 5 stars

Medical Sector

291st out of 1,351 stocks

Pharmaceutical Preparations Industry

137th out of 664 stocks

Analyst Opinion: 3.4Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Adamas Pharmaceuticals (NASDAQ:ADMS) Frequently Asked Questions

Is Adamas Pharmaceuticals a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Adamas Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Adamas Pharmaceuticals stock.
View analyst ratings for Adamas Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Adamas Pharmaceuticals?

Wall Street analysts have given Adamas Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Adamas Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Adamas Pharmaceuticals' next earnings date?

Adamas Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Adamas Pharmaceuticals

How were Adamas Pharmaceuticals' earnings last quarter?

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) posted its earnings results on Sunday, August, 8th. The specialty pharmaceutical company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.02.
View Adamas Pharmaceuticals' earnings history

How has Adamas Pharmaceuticals' stock been impacted by Coronavirus?

Adamas Pharmaceuticals' stock was trading at $3.05 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ADMS stock has increased by 58.0% and is now trading at $4.82.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ADMS?

4 brokerages have issued 1 year price objectives for Adamas Pharmaceuticals' shares. Their forecasts range from $6.00 to $12.50. On average, they expect Adamas Pharmaceuticals' share price to reach $9.50 in the next twelve months. This suggests a possible upside of 97.1% from the stock's current price.
View analysts' price targets for Adamas Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Adamas Pharmaceuticals' key executives?

Adamas Pharmaceuticals' management team includes the following people:

What is Neil McFarlane's approval rating as Adamas Pharmaceuticals' CEO?

2 employees have rated Adamas Pharmaceuticals CEO Neil McFarlane on Neil McFarlane has an approval rating of 100% among Adamas Pharmaceuticals' employees. This puts Neil McFarlane in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Adamas Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adamas Pharmaceuticals investors own include Rite Aid (RAD), Sorrento Therapeutics (SRNE), Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Sangamo Therapeutics (SGMO), Dynavax Technologies (DVAX), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Exelixis (EXEL) and Nabriva Therapeutics (NBRV).

What is Adamas Pharmaceuticals' stock symbol?

Adamas Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMS."

Who are Adamas Pharmaceuticals' major shareholders?

Adamas Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (11.56%), AIGH Capital Management LLC (5.34%), Point72 Asset Management L.P. (4.94%), Vanguard Group Inc. (3.84%), Renaissance Technologies LLC (1.72%) and BlackRock Inc. (1.65%). Company insiders that own Adamas Pharmaceuticals stock include Christopher B Prentiss, Martha J Demski, Spyridon Papapetropoulos and Vijay Shreedhar.
View institutional ownership trends for Adamas Pharmaceuticals

Which institutional investors are selling Adamas Pharmaceuticals stock?

ADMS stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, Susquehanna International Group LLP, Squarepoint Ops LLC, Price T Rowe Associates Inc. MD, Renaissance Technologies LLC, Deutsche Bank AG, and DCF Advisers LLC. Company insiders that have sold Adamas Pharmaceuticals company stock in the last year include Christopher B Prentiss, Martha J Demski, and Vijay Shreedhar.
View insider buying and selling activity for Adamas Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Adamas Pharmaceuticals stock?

ADMS stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., MAI Capital Management, AIGH Capital Management LLC, FMR LLC, BlackRock Inc., State Street Corp, Bridgeway Capital Management LLC, and GSA Capital Partners LLP.
View insider buying and selling activity for Adamas Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Adamas Pharmaceuticals?

Shares of ADMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adamas Pharmaceuticals' stock price today?

One share of ADMS stock can currently be purchased for approximately $4.82.

How much money does Adamas Pharmaceuticals make?

Adamas Pharmaceuticals has a market capitalization of $219.77 million and generates $74.46 million in revenue each year. The specialty pharmaceutical company earns $-57,400,000.00 in net income (profit) each year or ($2.03) on an earnings per share basis.

How many employees does Adamas Pharmaceuticals have?

Adamas Pharmaceuticals employs 138 workers across the globe.

What is Adamas Pharmaceuticals' official website?

The official website for Adamas Pharmaceuticals is

Where are Adamas Pharmaceuticals' headquarters?

Adamas Pharmaceuticals is headquartered at 1900 POWELL ST. SUITE 1000, EMERYVILLE CA, 94608.

How can I contact Adamas Pharmaceuticals?

Adamas Pharmaceuticals' mailing address is 1900 POWELL ST. SUITE 1000, EMERYVILLE CA, 94608. The specialty pharmaceutical company can be reached via phone at (510) 450-3500 or via email at [email protected].

This page was last updated on 9/23/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.